Adam Neidert
Biochemistry, Genetics and Molecular Biology · University of Michigan
Publications
48
Citations
1,103
Est. group size
~5
Recurring co-author estimate
Active years
27
Publishing since 2000
Typically publishes in teams of ~8 · 0% small-team papers (≤3 authors) · across 13 venues
- EBF2 variant identified in a patient with atypical partial lipodystrophy causes adipose fibrosis and dysfunction
Journal of Clinical Investigation · 2026
- Changes After Leptin Administration in Partial Lipodystrophy and Factors Associated With Hepatic and Metabolic Response
Journal of the Endocrine Society · 2025
- Genetics Evaluation Outcomes From an Academic Multidisciplinary Atypical Diabetes Program
Journal of the Endocrine Society · 2025
- Efficacy and Safety of Glucagon-Like Peptide 1 Agonists in a Retrospective Study of Patients With Familial Partial Lipodystrophy
Diabetes Care · 2024
- Early B-cell transcription factor-2 defect as a novel cause of lipodystrophy: disruption of the adipose tissue character and integrity
medRxiv · 2024
- Preclinical, randomized phase 1, and compassionate use evaluation of REGN4461, a leptin receptor agonist antibody for leptin deficiency
Science Translational Medicine · 2023
- FRI059 Long-term Follow-up On Partial Lipodystrophy Treated With Leptin Receptor Agonist Mibavademab(REGN4461)
Journal of the Endocrine Society · 2023
- SAT080 Partnering With Medical Genetics To Provide Molecular Diagnosis In Atypical Diabetes
Journal of the Endocrine Society · 2023
- RF24 | PSUN126 A Very-Low Calorie Diet Can Reduce Insulin Resistance and Cause Remission of Diabetes Mellitus and Hypertriglyceridemia in a Patient With Familial Partial Lipodystrophy Type 2
Journal of the Endocrine Society · 2022
- PSUN138 Demonstration of Progressive Beta-Cell Failure in Familial Partial Lipodystrophy
Journal of the Endocrine Society · 2022
- Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study
Lipids in Health and Disease · 2021
- Endogenous Leptin Concentrations Poorly Predict Metreleptin Response in Patients With Partial Lipodystrophy
The Journal of Clinical Endocrinology & Metabolism · 2021
- Selective Targeting of Angiopoietin-like 3 (ANGPTL3) with Vupanorsen for the Treatment of Patients with Familial Partial Lipodystrophy (FPLD): Results of a Proof-of-Concept Study
Research Square · 2021
- The Long-Term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy
Journal of the Endocrine Society · 2021
- Inhibition of Angiopoietin-Like 3 (ANGPTL3) Reduces Adipose Tissue Insulin Resistance in Patients With Familial Partial Lipodystrophy
Journal of the Endocrine Society · 2021
- Journal of the Endocrine Society×16
- Diabetes Care×3
- Diabetes×3
- Clinical Endocrinology×2
- The Journal of Clinical Endocrinology & Metabolism×2
- Jessica N. Maung
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Elif A Oral
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Rasimcan Meral
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Noura Nachawi
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Donatella Gilio
Biochemistry, Genetics and Molecular Biology · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile